Accumulation of K-Ras codon 12 mutations in the F344 rat distal colon following azoxymethane exposure

Environmental and Molecular Mutagenesis

Volumn 52, Issue 5, 2011, Pages 409-418

  Mckinzie, Page B ^a   Parsons, Barbara L ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Carcinogenesis; Mode of action; Mutation detection method; Spontaneous mutation

Indexed keywords

AZOXYMETHANE; DNA;

AGE; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CODON; COLON; COLON CARCINOGENESIS; CONTROLLED STUDY; DNA ADDUCT; DNA REPAIR; DRUG EXPOSURE; FISCHER 344 RAT; GENE MUTATION; MALE; NONHUMAN; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; AZOXYMETHANE; CODON; COLON; GENES, RAS; MALE; MUTATION; POLYMERASE CHAIN REACTION; RATS; RATS, INBRED F344;

RATTUS;

EID: 79952817757     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20644     Document Type: Article

References (45)

1. American Cancer Society: Cancer Facts and Figures 2009. WHO Statistical Information System.
2. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. 2009. American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-2096.
3. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lovig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N. 2001. Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 85: 692-696.
4. Bos JL. 1988. The ras gene family and human carcinogenesis. Mutat Res 195: 255-271.
5. Cho KR, Vogelstein B. 1992. Genetic alterations in the adenoma-carcinoma sequence. Cancer 70: 1727-1731.
6. Engstrom PF. 2008. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy. Pharmacotherapy 28: 18S-22S.
7. Fiala ES. 1977. Investigations into the metabolism and mode of action of the colon carcinogens 1, 2-dimethylhydrazine and azoxymethane. Cancer 40: 2436-2445.
8. 6-methylguanine in a synthetic DNA polymer by an inducible activity in Escherichia coli. Biochem Biophys Res Commun 97: 654-659.
9. Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C, Kok CY, Jia M, Ewing R, Menzies A, Teague JW, Stratton MR, Futreal PA. 2010. COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Res 38: D652-D657.
10. Hirose Y, Yoshimi N, Makita H, Hara A, Tanaka T, Mori H. 1996. Early alterations of apoptosis and cell proliferation in azoxymethane-initiated rat colonic epithelium. Jpn J Cancer Res 87: 575-582.
11. Hong MY, Chapkin RS, Wild CP, Morris JS, Wang N, Carroll RJ, Turner ND, Lupton JR. 1999. Relationship between DNA adduct levels, repair enzyme, and apoptosis as a function of DNA methylation by azoxymethane. Cell Growth Differ 10: 749-758.
12. Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK, editors. 2009. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute.Bethesda MD, based on November 2008 SEER data submission, posted to the SEER web site, 2009.
13. Janssen KP, Abal M, El Marjou F, Louvard D, Robine S. 2005. Mouse models of K-ras-initiated carcinogenesis. Biochim Biophys Acta 1756: 145-154.
14. Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR, Vogelstein B, Kinzler KW. 1994. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 54: 5523-5526.
15. Kwon Y, Magnuson BA. 2007. Aging alters acute apoptotic response to azoxymethane in the colon of rats. Exp Gerontol 42: 1154-1161.
16. 6-methylguanine built into a unique site in a viral genome. Proc Natl Acad Sci USA 81: 6271-6275.
17. Markowitz SD, Bertagnolli MM. 2009. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 361: 2449-2460.
18. McKinzie PB, Parsons BL. 2002. Detection of rare K-ras codon 12 mutations using allele-specific competitive blocker PCR. Mutat Res 517: 209-220.
19. McKinzie PB, Delongchamp RR, Chen T, Parsons BL. 2006. ACB-PCR measurement of K-ras codon 12 mutant fractions in livers of Big Blue rats treated with N-hydroxy-2-acetylaminofluorene. Mutagen 21: 391-397.
20. Meng F, Knapp GW, Green T, Ross JA, Parsons BL. 2009. K-Ras mutant fraction in A/J mouse lung increases as a function of benzo[a]pyrene dose. Environ Mol Mutagen 51: 146-155.
21. Meng F, Bermudez E, McKinzie PB, Andersen ME, Clewell HJIII, Parsons BL. 2010. Measurement of tumor-associated mutations in the nasal mucosa of rats exposed to varying doses of formaldehyde. Regul Toxicol Pharmacol 57: 274-283.
22. Messier B. 1960. Renewal of the colonic epithelium of the rat. Am J Dig Dis 5: 833-835.
23. 6-methylguanine to a protein cysteine residue. J Biol Chem 255: 10569-10571.
24. Parsons BL, Heflich RH. 1998. Detection of a mouse H-ras codon 61 mutation using a modified allele-specific competitive blocker PCR genotypic selection method. Mutagen 13: 581-588.
25. Parsons BL, Beland FA, Von Tungeln LS, Delongchamp RR, Fu PP, Heflich RH. 2005a. Levels of 4-aminobiphenyl-induced somatic H-ras mutation in mouse liver DNA correlate with potential for liver tumor development. Mol Carcinog 42: 193-201.
26. Parsons BL, McKinzie PB, Heflich RH. 2005b. Allele-specific competitive blocker-PCR detection of rare base substitution. Methods Mol Biol 291: 235-245.
27. Parsons BL, Delongchamp RR, Beland FA, Heflich RH. 2006. Levels of H-ras codon 61 CAA to AAA mutation: Response to 4-ABP-treatment and Pms2-deficiency. Mutagen 21: 29-34.
28. Plesec TP, Hunt JL. 2009. KRAS mutation testing in colorectal cancer. Adv Anat Pathol 16: 196-203.
29. Pretlow TP, Brasitus TA, Fulton NC, Cheyer C, Kaplan EL. 1993. K-ras mutations in putative preneoplastic lesions in human colon. J Natl Cancer Inst 85: 2004-2007.
30. Quinlan MP, Settleman J. 2008. Explaining the preponderance of Kras mutations in human cancer: An isoform-specific function in stem cell expansion. Cell Cycle 7: 1332-1335.
31. 6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. Cell Cycle 9: 168-178.
32. Reddy BS. 2004. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ Mol Mutagen 44: 26-35.
33. Relan NK, Saeed A, Ponduri K, Fligiel SE, Dutta S, Majumdar AP. 1995. Identification and evaluation of the role of endogenous tyrosine kinases in azoxymethane induction of proliferative processes in the colonic mucosa of rats. Biochim Biophys Acta 1244: 368-376.
34. Shivapurkar N, Tang Z, Ferreira A, Nasim S, Garett C, Alabaster O. 1994. Sequential analysis of K-ras mutations in aberrant crypt foci and colonic tumors induced by azoxymethane in Fischer-344 rats on high-risk diet. Carcinogenesis 15: 775-778.
35. Shivapurkar N, Huang L, Ruggeri B, Swalsky PA, Bakker A, Finkelstein S, Frost A, Silverberg S. 1997. K-ras and p53 mutations in aberrant crypt foci and colonic tumors from colon cancer patients. Cancer Lett 115: 39-46.
36. Singh J, Kelloff G, Reddy BS. 1993. Intermediate biomarkers of colon cancer: Modulation of expression of ras oncogene by chemopreventive agents during azoxymethane induced colon carcinogenesis. Carcinogenesis 14: 699-704.
37. Singh J, Kulkarni N, Kelloff G, Reddy BS. 1994. Modulation of azoxymethane-induced mutational activation of ras protooncogenes by chemopreventive agents in colon carcinogenesis. Carcinogenesis 15: 1317-1323.
38. Smith AJ, Stern HS, Penner M, Hay K, Mitri A, Bapat BV, Gallinger S. 1994. Somatic APC, K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res 54: 5527-5530.
39. Sohn OS, Fiala ES, Requeijo SP, Weisburger JH, Gonzalez FJ. 2001. Differential effects of CYP2E1 status on the metabolic activation of the colon carcinogens azoxymethane and methylazoxymethanol. Cancer Res 61: 8435-8440.
40. Takahashi M, Wakabayashi K. 2004. Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci 95: 475-480.
41. Takayama T, Ohi M, Hayashi T, Miyanishi K, Nobuoka A, Nakajima T, Satoh T, Takimoto R, Kato J, Sakamaki S, et al. 2001. Analysis of K-ras APC, β-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology 121: 599-611.
42. Verkler TL, Couch LH, Howard PC, Parsons BL. 2005. Quantifying levels of p53 mutation in mouse skin tumors. Environ Mol Mutagen 45: 427-434.
43. Verkler TL, Delongchamp RR, Miller BJ, Webb PJ, Howard PC, Parsons BL. 2008. Simulated solar light-induced p53 mutagenesis in SKH-1 mouse skin: A dose-response assessment. Mol Carcinog 47: 599-607.
44. Vitale-Cross L, Amornphimoltham P, Fisher G, Molinolo AA, Gutkind JS. 2004. Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis. Cancer Res 64: 8804-8807.
45. Vivona AA, Shpitz B, Medline A, Bruce WR, Hay K, Ward MA, Stern HS, Gallinger S. 1993. K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. Carcinogenesis 14: 1777-1781.